{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T21:11:00Z","timestamp":1790457060283,"version":"4.1.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,5,18]],"date-time":"2017-05-18T00:00:00Z","timestamp":1495065600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s40265-017-0755-8","type":"journal-article","created":{"date-parts":[[2017,5,18]],"date-time":"2017-05-18T05:35:34Z","timestamp":1495085734000},"page":"1057-1068","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Advances in the Development of Janus Kinase Inhibitors in Inflammatory Bowel Disease: Future Prospects"],"prefix":"10.1007","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8076-7046","authenticated-orcid":false,"given":"Mathurin","family":"Flamant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josselin","family":"Rigaill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Roblin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,18]]},"reference":[{"key":"755_CR1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4137\/CGast.S12731","volume":"6","author":"AE M\u2019Koma","year":"2013","unstructured":"M\u2019Koma AE. Inflammatory bowel disease: an expanding global health problem. Clin Med Insights Gastroenterol. 2013;6:33\u201347.","journal-title":"Clin Med Insights Gastroenterol"},{"issue":"7152","key":"755_CR2","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature06005","volume":"448","author":"RJ Xavier","year":"2007","unstructured":"Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448(7152):427\u201334.","journal-title":"Nature"},{"key":"755_CR3","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1146\/annurev-immunol-030409-101225","volume":"28","author":"A Kaser","year":"2010","unstructured":"Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol. 2010;28:573\u2013621.","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"755_CR4","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3748\/wjg.v20.i1.64","volume":"20","author":"J Pedersen","year":"2014","unstructured":"Pedersen J, Coskun M, Soendergaard C, Salem M, Nielsen OH. Inflammatory pathways of importance for management of inflammatory bowel disease. World J Gastroenterol. 2014;20(1):64\u201377.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"755_CR5","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1517\/14712598.2014.858695","volume":"14","author":"T Billiet","year":"2014","unstructured":"Billiet T, Rutgeerts P, Ferrante M, Van Assche G, Vermeire S. Targeting TNF-alpha for the treatment of inflammatory bowel disease. Expert Opin Biol Ther. 2014;14(1):75\u2013101.","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"755_CR6","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/ajg.2008.88","volume":"104","author":"JP Gisbert","year":"2009","unstructured":"Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn\u2019s disease: a review. Am J Gastroenterol. 2009;104(3):760\u20137.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"755_CR7","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/ajg.2011.60","volume":"106","author":"V Billioud","year":"2011","unstructured":"Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn\u2019s disease: a systematic review. Am J Gastroenterol. 2011;106(4):674\u201384.","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"755_CR8","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","volume":"369","author":"BG Feagan","year":"2013","unstructured":"Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699\u2013710.","journal-title":"N Engl J Med"},{"issue":"8","key":"755_CR9","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","volume":"369","author":"WJ Sandborn","year":"2013","unstructured":"Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2013;369(8):711\u201321.","journal-title":"N Engl J Med"},{"issue":"20","key":"755_CR10","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","volume":"375","author":"BG Feagan","year":"2016","unstructured":"Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2016;375(20):1946\u201360.","journal-title":"N Engl J Med"},{"issue":"4","key":"755_CR11","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.semcdb.2008.07.020","volume":"19","author":"AF Wilks","year":"2008","unstructured":"Wilks AF. The JAK kinases: not just another kinase drug discovery target. Semin Cell Dev Biol. 2008;19(4):319\u201328.","journal-title":"Semin Cell Dev Biol"},{"issue":"14","key":"755_CR12","doi-asserted-by":"crossref","first-page":"6374","DOI":"10.1073\/pnas.91.14.6374","volume":"91","author":"M Kawamura","year":"1994","unstructured":"Kawamura M, McVicar DW, Johnston JA, Blake TB, Chen YQ, Lal BK, et al. Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes. Proc Natl Acad Sci USA. 1994;91(14):6374\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"755_CR13","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","volume":"111","author":"R Roskoski Jr","year":"2016","unstructured":"Roskoski R Jr. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. Pharmacol Res. 2016;111:784\u2013803.","journal-title":"Pharmacol Res"},{"issue":"2","key":"755_CR14","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/0016-5085(92)90098-J","volume":"102","author":"V Gross","year":"1992","unstructured":"Gross V, Andus T, Caesar I, Roth M, Scholmerich J. Evidence for continuous stimulation of interleukin-6 production in Crohn\u2019s disease. Gastroenterology. 1992;102(2):514\u20139.","journal-title":"Gastroenterology"},{"issue":"5","key":"755_CR15","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/0016-5085(93)90336-B","volume":"104","author":"JS Hyams","year":"1993","unstructured":"Hyams JS, Fitzgerald JE, Treem WR, Wyzga N, Kreutzer DL. Relationship of functional and antigenic interleukin 6 to disease activity in inflammatory bowel disease. Gastroenterology. 1993;104(5):1285\u201392.","journal-title":"Gastroenterology"},{"issue":"2","key":"755_CR16","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/BOR.0000000000000255","volume":"28","author":"X Liu","year":"2016","unstructured":"Liu X, Jones GW, Choy EH, Jones SA. The biology behind interleukin-6 targeted interventions. Curr Opin Rheumatol. 2016;28(2):152\u201360.","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"755_CR17","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.4049\/jimmunol.0801217","volume":"184","author":"S Matsumoto","year":"2010","unstructured":"Matsumoto S, Hara T, Mitsuyama K, Yamamoto M, Tsuruta O, Sata M, et al. Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6\/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model. J Immunol. 2010;184(3):1543\u201351.","journal-title":"J Immunol"},{"issue":"9","key":"755_CR18","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/ni1488","volume":"8","author":"L Zhou","year":"2007","unstructured":"Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T, et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol. 2007;8(9):967\u201374.","journal-title":"Nat Immunol"},{"issue":"1","key":"755_CR19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.clim.2008.08.018","volume":"130","author":"O Dienz","year":"2009","unstructured":"Dienz O, Rincon M. The effects of IL-6 on CD4 T cell responses. Clin Immunol. 2009;130(1):27\u201333.","journal-title":"Clin Immunol"},{"issue":"3","key":"755_CR20","doi-asserted-by":"crossref","first-page":"e85345","DOI":"10.1371\/journal.pone.0085345","volume":"9","author":"R Al-Sadi","year":"2014","unstructured":"Al-Sadi R, Ye D, Boivin M, Guo S, Hashimi M, Ereifej L, et al. Interleukin-6 modulation of intestinal epithelial tight junction permeability is mediated by JNK pathway activation of claudin-2 gene. PLoS One. 2014;9(3):e85345.","journal-title":"PLoS One"},{"issue":"12","key":"755_CR21","doi-asserted-by":"crossref","first-page":"e114195","DOI":"10.1371\/journal.pone.0114195","volume":"9","author":"KA Kuhn","year":"2014","unstructured":"Kuhn KA, Manieri NA, Liu TC, Stappenbeck TS. IL-6 stimulates intestinal epithelial proliferation and repair after injury. PLoS One. 2014;9(12):e114195.","journal-title":"PLoS One"},{"issue":"4","key":"755_CR22","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1177\/0394632015600535","volume":"28","author":"C Defendenti","year":"2015","unstructured":"Defendenti C, Sarzi-Puttini P, Saibeni S, Bollani S, Bruno S, Almasio PL, et al. Significance of serum Il-9 levels in inflammatory bowel disease. Int J Immunopathol Pharmacol. 2015;28(4):569\u201375.","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"5","key":"755_CR23","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1136\/gutjnl-2013-305947","volume":"64","author":"N Nalleweg","year":"2015","unstructured":"Nalleweg N, Chiriac MT, Podstawa E, Lehmann C, Rau TT, Atreya R, et al. IL-9 and its receptor are predominantly involved in the pathogenesis of UC. Gut. 2015;64(5):743\u201355.","journal-title":"Gut"},{"issue":"7","key":"755_CR24","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/ni.2920","volume":"15","author":"K Gerlach","year":"2014","unstructured":"Gerlach K, Hwang Y, Nikolaev A, Atreya R, Dornhoff H, Steiner S, et al. TH9 cells that express the transcription factor PU.1 drive T cell-mediated colitis via IL-9 receptor signaling in intestinal epithelial cells. Nat Immunol. 2014;15(7):676\u201386.","journal-title":"Nat Immunol"},{"issue":"4","key":"755_CR25","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.immuni.2008.02.017","volume":"28","author":"YP Rubtsov","year":"2008","unstructured":"Rubtsov YP, Rasmussen JP, Chi EY, Fontenot J, Castelli L, Ye X, et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity. 2008;28(4):546\u201358.","journal-title":"Immunity"},{"issue":"2","key":"755_CR26","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.clim.2012.02.005","volume":"143","author":"SR Hofmann","year":"2012","unstructured":"Hofmann SR, Rosen-Wolff A, Tsokos GC, Hedrich CM. Biological properties and regulation of IL-10 related cytokines and their contribution to autoimmune disease and tissue injury. Clin Immunol. 2012;143(2):116\u201327.","journal-title":"Clin Immunol"},{"issue":"5","key":"755_CR27","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S1074-7613(03)00296-6","volume":"19","author":"G Trinchieri","year":"2003","unstructured":"Trinchieri G, Pflanz S, Kastelein RA. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity. 2003;19(5):641\u20134.","journal-title":"Immunity"},{"issue":"1","key":"755_CR28","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1084\/jem.181.1.399","volume":"181","author":"CM Bacon","year":"1995","unstructured":"Bacon CM, McVicar DW, Ortaldo JR, Rees RC, O\u2019Shea JJ, Johnston JA. Interleukin 12 (IL-12) induces tyrosine phosphorylation of JAK2 and TYK2: differential use of Janus family tyrosine kinases by IL-2 and IL-12. J Exp Med. 1995;181(1):399\u2013404.","journal-title":"J Exp Med"},{"key":"755_CR29","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1146\/annurev.immunol.22.012703.104758","volume":"25","author":"RA Kastelein","year":"2007","unstructured":"Kastelein RA, Hunter CA, Cua DJ. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol. 2007;25:221\u201342.","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"755_CR30","doi-asserted-by":"crossref","first-page":"G827","DOI":"10.1152\/ajpgi.00513.2005","volume":"290","author":"S Brand","year":"2006","unstructured":"Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, Otte JM, et al. IL-22 is increased in active Crohn\u2019s disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am J Physiol Gastrointest Liver Physiol. 2006;290(4):G827\u201338.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"7583","key":"755_CR31","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nature16460","volume":"528","author":"CA Lindemans","year":"2015","unstructured":"Lindemans CA, Calafiore M, Mertelsmann AM, O\u2019Connor MH, Dudakov JA, Jenq RR, et al. Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regeneration. Nature. 2015;528(7583):560\u20134.","journal-title":"Nature"},{"issue":"7","key":"755_CR32","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1074\/jbc.271.7.3562","volume":"271","author":"MF Brizzi","year":"1996","unstructured":"Brizzi MF, Aronica MG, Rosso A, Bagnara GP, Yarden Y, Pegoraro L. Granulocyte-macrophage colony-stimulating factor stimulates JAK2 signaling pathway and rapidly activates p93fes, STAT1 p91, and STAT3 p92 in polymorphonuclear leukocytes. J Biol Chem. 1996;271(7):3562\u20137.","journal-title":"J Biol Chem"},{"key":"755_CR33","unstructured":"Han X, Uchida K, Jurickova I, Koch D, Willson T, Samson C, et al. Granulocyte-macrophage colony-stimulating factor autoantibodies in murine ileitis and progressive ileal Crohn\u2019s disease. Gastroenterology. 2009;136(4):1261\u201371, e1\u20133."},{"key":"755_CR34","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1600-065X.2008.00698.x","volume":"226","author":"SY Zhang","year":"2008","unstructured":"Zhang SY, Boisson-Dupuis S, Chapgier A, Yang K, Bustamante J, Puel A, et al. Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha\/beta, IFN-gamma, and IFN-lambda in host defense. Immunol Rev. 2008;226:29\u201340.","journal-title":"Immunol Rev"},{"issue":"9","key":"755_CR35","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/ni828","volume":"3","author":"X Hu","year":"2002","unstructured":"Hu X, Herrero C, Li WP, Antoniv TT, Falck-Pedersen E, Koch AE, et al. Sensitization of IFN-gamma Jak-STAT signaling during macrophage activation. Nat Immunol. 2002;3(9):859\u201366.","journal-title":"Nat Immunol"},{"issue":"5","key":"755_CR36","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.immuni.2009.05.001","volume":"30","author":"L Zhou","year":"2009","unstructured":"Zhou L, Chong MM, Littman DR. Plasticity of CD4\u00a0+\u00a0T cell lineage differentiation. Immunity. 2009;30(5):646\u201355.","journal-title":"Immunity"},{"issue":"4","key":"755_CR37","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.immuni.2009.09.002","volume":"31","author":"X Hu","year":"2009","unstructured":"Hu X, Ivashkiv LB. Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases. Immunity. 2009;31(4):539\u201350.","journal-title":"Immunity"},{"key":"755_CR38","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/B978-0-444-62652-3.00004-1","volume":"52","author":"CJ Menet","year":"2013","unstructured":"Menet CJ, Rompaey LV, Geney R. Advances in the discovery of selective JAK inhibitors. Prog Med Chem. 2013;52:153\u2013223.","journal-title":"Prog Med Chem"},{"issue":"12","key":"755_CR39","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1021\/jm401490p","volume":"57","author":"JD Clark","year":"2014","unstructured":"Clark JD, Flanagan ME, Telliez JB. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem. 2014;57(12):5023\u201338.","journal-title":"J Med Chem"},{"issue":"1","key":"755_CR40","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nbt1358","volume":"26","author":"MW Karaman","year":"2008","unstructured":"Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008;26(1):127\u201332.","journal-title":"Nat Biotechnol"},{"issue":"7","key":"755_CR41","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","volume":"367","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012;367(7):616\u201324.","journal-title":"N Engl J Med"},{"key":"755_CR42","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12876-015-0239-9","volume":"15","author":"J Panes","year":"2015","unstructured":"Panes J, Su C, Bushmakin AG, Cappelleri JC, Mamolo C, Healey P. Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes. BMC Gastroenterol. 2015;15:14.","journal-title":"BMC Gastroenterol"},{"issue":"11","key":"755_CR43","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/ecco-jcc\/jjw107","volume":"10","author":"J Panes","year":"2016","unstructured":"Panes J, Su C, Bushmakin AG, Cappelleri JC, Healey P. Direct and indirect effects of tofacitinib on treatment satisfaction in patients with ulcerative colitis. J Crohns Colitis. 2016;10(11):1310\u20135.","journal-title":"J Crohns Colitis"},{"issue":"1","key":"755_CR44","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.gastro.2015.09.001","volume":"150","author":"WJ Sandborn","year":"2016","unstructured":"Sandborn WJ, Panes J, Zhang H, Yu D, Niezychowski W, Su C. Correlation between concentrations of fecal calprotectin and outcomes of patients with ulcerative colitis in a phase 2 trial. Gastroenterology. 2016;150(1):96\u2013102.","journal-title":"Gastroenterology"},{"issue":"18","key":"755_CR45","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE, D'Haens GR, Vermeire S, Schreiber S et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723\u201336. doi: 10.1056\/NEJMoa1606910 .","journal-title":"N Engl J Med."},{"key":"755_CR46","doi-asserted-by":"crossref","unstructured":"Sandborn WJ, Ghosh S, Panes J, Vranic I, Wang W, Niezychowski W, et al. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2014;12(9):1485\u201393.e2.","DOI":"10.1016\/j.cgh.2014.01.029"},{"key":"755_CR47","doi-asserted-by":"publisher","unstructured":"Panes J, Sandborn WJ, Schreiber S, Sands BE, Vermeire S, D\u2019Haens G, et al. Tofacitinib for induction and maintenance therapy of Crohn\u2019s disease: results of two phase IIb randomised placebo-controlled trials. Gut. doi: 10.1136\/gutjnl-2016-312735 . Epub 16 Feb 2017.","DOI":"10.1136\/gutjnl-2016-312735"},{"issue":"6","key":"755_CR48","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","volume":"367","author":"RF Vollenhoven van","year":"2012","unstructured":"van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garcia Meijide JA, Wagner S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367(6):508\u201319.","journal-title":"N Engl J Med"},{"issue":"6","key":"755_CR49","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","volume":"367","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367(6):495\u2013507.","journal-title":"N Engl J Med"},{"issue":"10","key":"755_CR50","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/art.38745","volume":"66","author":"KL Winthrop","year":"2014","unstructured":"Winthrop KL, Yamanaka H, Valdez H, Mortensen E, Chew R, Krishnaswami S, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66(10):2675\u201384.","journal-title":"Arthritis Rheumatol"},{"issue":"10066","key":"755_CR51","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","volume":"389","author":"S Vermeire","year":"2017","unstructured":"Vermeire S, Schreiber S, Petryka R, Kuehbacher T, Hebuterne X, Roblin X, et al. Clinical remission in patients with moderate-to-severe Crohn\u2019s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017;389(10066):266\u201375.","journal-title":"Lancet"},{"key":"755_CR52","doi-asserted-by":"publisher","unstructured":"Kavanaugh A, Kremer J, Ponce L, Cseuz R, Reshetko OV, Stanislavchuk M, et al. Filgotinib (GLPG0634\/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). Ann Rheum Dis. doi: 10.1136\/annrheumdis-2016-210105 . Epub 19 Dec 2016.","DOI":"10.1136\/annrheumdis-2016-210105"},{"key":"755_CR53","doi-asserted-by":"crossref","unstructured":"Namour F, Desrivot J, Van der Aa A, Harrison P, Tasset C, van\u2019t Klooster G. Clinical confirmation that the selective JAK1 inhibitor filgotinib (GLPG0634) has a low liability for drug\u2013drug interactions. Drug Metab Lett. 2016;10(1):38\u201348.","DOI":"10.2174\/1872312810666151223103353"},{"issue":"12","key":"755_CR54","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s40262-016-0419-y","volume":"55","author":"MF Mohamed","year":"2016","unstructured":"Mohamed MF, Camp HS, Jiang P, Padley RJ, Asatryan A, Othman AA. Pharmacokinetics, safety and tolerability of ABT-494, a novel selective JAK 1 inhibitor, in healthy volunteers and subjects with rheumatoid arthritis. Clin Pharmacokinet. 2016;55(12):1547\u201358.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"755_CR55","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.crohns.2011.07.011","volume":"6","author":"MB Sprakes","year":"2012","unstructured":"Sprakes MB, Ford AC, Warren L, Greer D, Hamlin J. Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn\u2019s disease: a large single centre experience. J Crohns Colitis. 2012;6(2):143\u201353.","journal-title":"J Crohns Colitis"},{"issue":"9317","key":"755_CR56","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541\u20139.","journal-title":"Lancet"},{"key":"755_CR57","doi-asserted-by":"crossref","unstructured":"Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):644\u201359, quiz 60.","DOI":"10.1038\/ajg.2011.73"},{"issue":"7","key":"755_CR58","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/ajg.2014.110","volume":"109","author":"MH Mosli","year":"2014","unstructured":"Mosli MH, Sandborn WJ, Kim RB, Khanna R, Al-Judaibi B, Feagan BG. Toward a personalized medicine approach to the management of inflammatory bowel disease. Am J Gastroenterol. 2014;109(7):994\u20131004.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"755_CR59","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nm.3462","volume":"20","author":"R Atreya","year":"2014","unstructured":"Atreya R, Neumann H, Neufert C, Waldner MJ, Billmeier U, Zopf Y, et al. In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn\u2019s disease. Nat Med. 2014;20(3):313\u20138.","journal-title":"Nat Med"},{"issue":"7","key":"755_CR60","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1080\/00365520802699278","volume":"44","author":"K Bendtzen","year":"2009","unstructured":"Bendtzen K, Ainsworth M, Steenholdt C, Thomsen OO, Brynskov J. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol. 2009;44(7):774\u201381.","journal-title":"Scand J Gastroenterol"},{"key":"755_CR61","doi-asserted-by":"crossref","unstructured":"Vermeire S, Schreiber S, Petryka R, Kuehbacher T, Hebuterne X, Roblin X, et al. Maintenance of clinical effect in patients with moderate-to-severe Crohn\u2019s disease treated with filgotinib, a selective JAK1 inhibitor: exploratory 20-week data analysis of the phase 2 FITZROY study. European Crohn's and colitis organisation. 2017. Available at: https:\/\/www.ecco-ibd.eu\/index.php\/publications\/congress-abstract-s\/abstracts-2017\/item\/op023-maintenance-of-clinical-effect-in-patients-with-moderate-to-severe-crohn-s-disease-treated-with-filgotinib-a-selective-jak1-inhibitor-exploratory-20-week-data-analysis-of-the-phase-2-fitzroy-study.html . Accessed 10 May 2017.","DOI":"10.1093\/ecco-jcc\/jjx002.022"},{"key":"755_CR62","doi-asserted-by":"crossref","unstructured":"Beattie D, Tsuruda P, Shen F,\u00a0Brassil P, Langrish C, Janc J, et al. TD-1473, a novel, potent, and orally administered, GI-targeted, pan-Janus kinase (JAK) inhibitor. European Crohn's and colitis organisation. 2016. Available at: https:\/\/www.ecco-ibd.eu\/index.php\/publications\/congress-abstract-s\/abstracts-2016\/item\/p069-td-1473-a-novel-potent-and-orally-administered-gi-targeted-pan-janus-kinase-jak-inhibitor.html . Accessed 10 May 2017.","DOI":"10.1093\/ecco-jcc\/jjw019.188"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-017-0755-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0755-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0755-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T16:11:57Z","timestamp":1569341517000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-017-0755-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,18]]},"references-count":62,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["755"],"URL":"https:\/\/doi.org\/10.1007\/s40265-017-0755-8","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727629246.793568158","asserted-by":"object"}]},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,18]]}}}